General Information of Drug (ID: DMIP5K7)

Drug Name
N,N-Dimethyl-3,3-diphenylpropan-1-amine Drug Info
Synonyms
3,3-Diphenyl-N-dimethylpropylamine; 4646-55-3; Oprea1_032403; N,N-Dimethyl-3,3-diphenylpropan-1-amine; AC1Q3WP9; AC1L45WF; diphenylalkylamine (DPA), 5c; SCHEMBL1802493; 3,3-Diphenylpropyldimethylamine; CHEMBL610739; CTK1C5217; BDBM35934; DTXSID90196845; (3,3-diphenylpropyl)dimethylamine; ZINC1679452; 3,3-diphenyl-N,N-dimethylpropylamine; AKOS016035475; Benzenepropanamine, N,N-dimethyl-gamma-phenyl-
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
151221
CAS Number
CAS 4646-55-3
TTD Drug ID
DMIP5K7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [3]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [4]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [5]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [6]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [7]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [8]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [9]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [10]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histamine H1 receptor (H1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [12]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [13]
Azelastine DMXTMBJ Allergic conjunctivitis 9A60.02 Approved [14]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [15]
Cinnarizine DM7U5QJ Meniere disease AB31.0 Approved [16]
Diphenhydramine DMKQTBA Hyperemesis gravidarum Approved [14]
Doxepin DMPI98T Anxiety Approved [17]
Chlorpheniramine DM5URA2 Allergic rhinitis CA08.0 Approved [14]
Epinastine DMX0K3Q Allergic conjunctivitis 9A60.02 Approved [18]
Desloratadine DM56YN7 Allergic rhinitis CA08.0 Approved [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [1]
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Inhibitor [1]

References

1 Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
2 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
3 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
4 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
6 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
7 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
9 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
10 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
11 Clinical pipeline report, company report or official report of Lundbeck.
12 Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
13 Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
14 Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
15 Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
16 Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
17 Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
18 Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
19 Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.